Angio-oedema as an unusual tolerable side effect of voriconazole therapy
Dr.Lütfi K rdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey Correspondence Serap Gençer segencer{at}tnn.net Received 20 March 2007 Accepted 7 April 2008 Voriconazole (VRC) has not previously been reported to cause angio-oedema....
Gespeichert in:
| Veröffentlicht in: | Journal of medical microbiology 2008-08, Vol.57 (8), p.1028-1031 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1031 |
|---|---|
| container_issue | 8 |
| container_start_page | 1028 |
| container_title | Journal of medical microbiology |
| container_volume | 57 |
| creator | Gencer, Serap Ozer, Serdar Demirhan, Guler Ak, Oznur Batirel, Ayse |
| description | Dr.Lütfi K rdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
Correspondence Serap Gençer segencer{at}tnn.net
Received 20 March 2007
Accepted 7 April 2008
Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.
Abbreviations: AmB, amphotericin B; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IA, invasive aspergillosis; VRC, voriconazole. |
| doi_str_mv | 10.1099/jmm.0.47299-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20934674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20934674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-99693689da997b49ee0df25f7baf12609593931775f3fc97960b47eb0b0b34a93</originalsourceid><addsrcrecordid>eNpF0E1v1DAQgGELgei2cOSKfKHikmX8kThzrCpKkSr1AmfLSca7rpJ4sRNQ--tx2VWRD748mhm9jH0QsBWA-OVhmraw1UYiVvCKbYQ2qqobrV-zDYCUlWxEfcbOc34AEEYpfMvORNvItgazYbdX8y7EKtJAk-MuczfzdV7z6ka-xJGS60biOQzEyXvqFx49_x1T6OPsngrgy76gw-M79sa7MdP703_Bft58_XF9W93df_t-fXVX9VrqpUJsUDUtDg7RdBqJYPCy9qZzXsgGsEaFShhTe-V7NNhApw11UJ7SDtUFuzzOPaT4a6W82CnknsbRzRTXbCWg0o3RBVZH2KeYcyJvDylMLj1aAfY5nS3pLNh_6SwU__E0eO0mGv7rU6sCPp2Ay70bfXJzH_KLk1C3siQu7vPR7cNu_ycksjuap1DO6EJ8Xlob25YLZKv-AoQihFU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20934674</pqid></control><display><type>article</type><title>Angio-oedema as an unusual tolerable side effect of voriconazole therapy</title><source>MEDLINE</source><source>Microbiology Society</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gencer, Serap ; Ozer, Serdar ; Demirhan, Guler ; Ak, Oznur ; Batirel, Ayse</creator><creatorcontrib>Gencer, Serap ; Ozer, Serdar ; Demirhan, Guler ; Ak, Oznur ; Batirel, Ayse</creatorcontrib><description>Dr.Lütfi K rdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
Correspondence Serap Gençer segencer{at}tnn.net
Received 20 March 2007
Accepted 7 April 2008
Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.
Abbreviations: AmB, amphotericin B; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IA, invasive aspergillosis; VRC, voriconazole.</description><identifier>ISSN: 0022-2615</identifier><identifier>EISSN: 1473-5644</identifier><identifier>DOI: 10.1099/jmm.0.47299-0</identifier><identifier>PMID: 18628507</identifier><identifier>CODEN: JMMIAV</identifier><language>eng</language><publisher>Reading: Soc General Microbiol</publisher><subject>Adult ; Allergic diseases ; Angioedema - chemically induced ; Angioedema - drug therapy ; Antifungal Agents - administration & dosage ; Antifungal Agents - adverse effects ; Aspergillosis - drug therapy ; Aspergillus ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; Histamine H1 Antagonists - administration & dosage ; Histamine H1 Antagonists - therapeutic use ; Humans ; Immunopathology ; Infectious diseases ; Infusions, Intravenous ; Medical sciences ; Microbiology ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Skin allergic diseases. Stinging insect allergies ; Treatment Outcome ; Triazoles - administration & dosage ; Triazoles - adverse effects ; Voriconazole</subject><ispartof>Journal of medical microbiology, 2008-08, Vol.57 (8), p.1028-1031</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-99693689da997b49ee0df25f7baf12609593931775f3fc97960b47eb0b0b34a93</citedby><cites>FETCH-LOGICAL-c424t-99693689da997b49ee0df25f7baf12609593931775f3fc97960b47eb0b0b34a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3746,3747,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20582001$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18628507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gencer, Serap</creatorcontrib><creatorcontrib>Ozer, Serdar</creatorcontrib><creatorcontrib>Demirhan, Guler</creatorcontrib><creatorcontrib>Ak, Oznur</creatorcontrib><creatorcontrib>Batirel, Ayse</creatorcontrib><title>Angio-oedema as an unusual tolerable side effect of voriconazole therapy</title><title>Journal of medical microbiology</title><addtitle>J Med Microbiol</addtitle><description>Dr.Lütfi K rdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
Correspondence Serap Gençer segencer{at}tnn.net
Received 20 March 2007
Accepted 7 April 2008
Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.
Abbreviations: AmB, amphotericin B; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IA, invasive aspergillosis; VRC, voriconazole.</description><subject>Adult</subject><subject>Allergic diseases</subject><subject>Angioedema - chemically induced</subject><subject>Angioedema - drug therapy</subject><subject>Antifungal Agents - administration & dosage</subject><subject>Antifungal Agents - adverse effects</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillus</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Histamine H1 Antagonists - administration & dosage</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><subject>Treatment Outcome</subject><subject>Triazoles - administration & dosage</subject><subject>Triazoles - adverse effects</subject><subject>Voriconazole</subject><issn>0022-2615</issn><issn>1473-5644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1v1DAQgGELgei2cOSKfKHikmX8kThzrCpKkSr1AmfLSca7rpJ4sRNQ--tx2VWRD748mhm9jH0QsBWA-OVhmraw1UYiVvCKbYQ2qqobrV-zDYCUlWxEfcbOc34AEEYpfMvORNvItgazYbdX8y7EKtJAk-MuczfzdV7z6ka-xJGS60biOQzEyXvqFx49_x1T6OPsngrgy76gw-M79sa7MdP703_Bft58_XF9W93df_t-fXVX9VrqpUJsUDUtDg7RdBqJYPCy9qZzXsgGsEaFShhTe-V7NNhApw11UJ7SDtUFuzzOPaT4a6W82CnknsbRzRTXbCWg0o3RBVZH2KeYcyJvDylMLj1aAfY5nS3pLNh_6SwU__E0eO0mGv7rU6sCPp2Ay70bfXJzH_KLk1C3siQu7vPR7cNu_ycksjuap1DO6EJ8Xlob25YLZKv-AoQihFU</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Gencer, Serap</creator><creator>Ozer, Serdar</creator><creator>Demirhan, Guler</creator><creator>Ak, Oznur</creator><creator>Batirel, Ayse</creator><general>Soc General Microbiol</general><general>Society for General Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>M7N</scope></search><sort><creationdate>20080801</creationdate><title>Angio-oedema as an unusual tolerable side effect of voriconazole therapy</title><author>Gencer, Serap ; Ozer, Serdar ; Demirhan, Guler ; Ak, Oznur ; Batirel, Ayse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-99693689da997b49ee0df25f7baf12609593931775f3fc97960b47eb0b0b34a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Allergic diseases</topic><topic>Angioedema - chemically induced</topic><topic>Angioedema - drug therapy</topic><topic>Antifungal Agents - administration & dosage</topic><topic>Antifungal Agents - adverse effects</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillus</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Histamine H1 Antagonists - administration & dosage</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><topic>Treatment Outcome</topic><topic>Triazoles - administration & dosage</topic><topic>Triazoles - adverse effects</topic><topic>Voriconazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gencer, Serap</creatorcontrib><creatorcontrib>Ozer, Serdar</creatorcontrib><creatorcontrib>Demirhan, Guler</creatorcontrib><creatorcontrib>Ak, Oznur</creatorcontrib><creatorcontrib>Batirel, Ayse</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of medical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gencer, Serap</au><au>Ozer, Serdar</au><au>Demirhan, Guler</au><au>Ak, Oznur</au><au>Batirel, Ayse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angio-oedema as an unusual tolerable side effect of voriconazole therapy</atitle><jtitle>Journal of medical microbiology</jtitle><addtitle>J Med Microbiol</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>57</volume><issue>8</issue><spage>1028</spage><epage>1031</epage><pages>1028-1031</pages><issn>0022-2615</issn><eissn>1473-5644</eissn><coden>JMMIAV</coden><abstract>Dr.Lütfi K rdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
Correspondence Serap Gençer segencer{at}tnn.net
Received 20 March 2007
Accepted 7 April 2008
Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.
Abbreviations: AmB, amphotericin B; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IA, invasive aspergillosis; VRC, voriconazole.</abstract><cop>Reading</cop><pub>Soc General Microbiol</pub><pmid>18628507</pmid><doi>10.1099/jmm.0.47299-0</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2615 |
| ispartof | Journal of medical microbiology, 2008-08, Vol.57 (8), p.1028-1031 |
| issn | 0022-2615 1473-5644 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20934674 |
| source | MEDLINE; Microbiology Society; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Allergic diseases Angioedema - chemically induced Angioedema - drug therapy Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Aspergillosis - drug therapy Aspergillus Biological and medical sciences Female Fundamental and applied biological sciences. Psychology Histamine H1 Antagonists - administration & dosage Histamine H1 Antagonists - therapeutic use Humans Immunopathology Infectious diseases Infusions, Intravenous Medical sciences Microbiology Pyrimidines - administration & dosage Pyrimidines - adverse effects Skin allergic diseases. Stinging insect allergies Treatment Outcome Triazoles - administration & dosage Triazoles - adverse effects Voriconazole |
| title | Angio-oedema as an unusual tolerable side effect of voriconazole therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A31%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angio-oedema%20as%20an%20unusual%20tolerable%20side%20effect%20of%20voriconazole%20therapy&rft.jtitle=Journal%20of%20medical%20microbiology&rft.au=Gencer,%20Serap&rft.date=2008-08-01&rft.volume=57&rft.issue=8&rft.spage=1028&rft.epage=1031&rft.pages=1028-1031&rft.issn=0022-2615&rft.eissn=1473-5644&rft.coden=JMMIAV&rft_id=info:doi/10.1099/jmm.0.47299-0&rft_dat=%3Cproquest_cross%3E20934674%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20934674&rft_id=info:pmid/18628507&rfr_iscdi=true |